Last update 14 Mar 2026

BAY-1862864

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
CD22-Thorium-conjugate, Epratuzumab Th-227 conjugate, epratuzumab-227Th-conjugate
+ [2]
Target
CD22
Action
modulators
Mechanism
CD22 modulators(CD22 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
CD22-Positive Non-Hodgkin Lymphoma
Originator Organization
Bayer AGBayer AG
Active Organization-
Inactive Organization
Bayer AGBayer AG
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with BAY-1862864
NCT02581878
/ CompletedPhase 1
An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
100 Clinical Results associated with BAY-1862864
Login to view more data
100 Translational Medicine associated with BAY-1862864
Login to view more data
100 Patents (Medical) associated with BAY-1862864
Login to view more data
100 Deals associated with BAY-1862864
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD22-Positive Non-Hodgkin LymphomaPhase 1
Sweden
Bayer AGBayer AG
20 Nov 2015
CD22-Positive Non-Hodgkin LymphomaPhase 1
United Kingdom
Bayer AGBayer AG
20 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02581878 (Pubmed | Cancer Biother Radiopharm)
ManualManual
Phase 1
Non-Hodgkin Lymphoma
CD22 Positive
21
chhpfponkr(lrfgzfqjcc) = erdyizbioa wfbynkcwyh (xskbjiarwo )
View more
Positive
01 Oct 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free